Medical Genetics & Pediatric Neurology & Rheumatology & Internal Medicine
Lesch-Nyhan syndrome
Lesch-Nyhan syndrome (LNS) is a rare X-linked recessive metabolic disorder caused by a complete (or near-complete) deficiency in hypoxanthine-guanine phosphoribosyltransferase (HPRT — a key enzyme in purine metabolism) resulting from loss-of-function mutations in the HPRT1 gene located on chromosome Xq26.2–q26.3. It was first described in 1964 by Michael Lesch and William Nyhan in two brothers presenting the characteristic triad: severe hyperuricemia + neurological deficit (dystonia + spasticity + dysarthria) + compulsive self-mutilation behavior (biting of lips + fingers + gums — the most dramatic and pathognomonic sign). The prevalence is estimated at 1 in 380,000 male births. LNS almost exclusively affects boys (hemizygous males) — heterozygous carrier females are usually asymptomatic thanks to compensatory lyonization (preferential inactivation of the mutated X chromosome). HPRT deficiency blocks the purine salvage pathway → accumulation of 5-phosphoribosyl-1-pyrophosphate (PRPP) → hyperactivity of the de novo purine synthesis pathway → overproduction of uric acid → hyperuricemia + hyperuricosuria → consequences: urinary calculi + gout + urate nephropathy. However, the mechanisms by which HPRT deficiency causes neurological abnormalities and self-mutilation behaviors remain partially elucidated — dopaminergic dysfunction (reduction of dopaminergic neurons in the basal ganglia — striatum) is implicated. Allopurinol (xanthine oxidase inhibitor) normalizes uricemia but does not correct the neurological manifestations or self-mutilation behaviors.
Biochemistry, pathophysiology, and clinical manifestations
- Purine Metabolism and HPRT Deficiency Mechanisms: Normal purine metabolism: de novo synthesis pathway: purines are synthesized de novo from simple precursors (glycine + glutamine + CO₂ + formate) in 10 enzymatic steps → final product: IMP (inosine monophosphate) → AMP + GMP → terminal catabolism: AMP → adenosine → inosine → hypoxanthine → xanthine → uric acid (via xanthine oxidase) → GMP → guanosine → guanine → xanthine → uric acid → salvage pathway: the salvage pathway recycles free purine bases (hypoxanthine + guanine) into reusable nucleotides → hypoxanthine + PRPP → (HPRT) → IMP → recycled → guanine + PRPP → (HPRT) → GMP → recycled → APRT (adenine phosphoribosyltransferase): recycles adenine → AMP + mechanisms of HPRT deficiency in the SLN: HPRT deficiency → blockage of the salvage pathway → accumulation of PRPP (5-phosphoribosyl-1-pyrophosphate) → PRPP is the initial substrate of the de novo synthesis pathway → hyperactivation of the de novo pathway → overproduction of purines → overproduction of uric acid (urate is the end product of purine catabolism in humans—humans lack uricase unlike other mammals) → hyperuricemia + hyperuricosuria + clinical and biochemical consequences: urate-type urinary lithiasis (starting in early childhood — orange-colored sand in diapers = early sign) + uric acid nephropathy + early tophaceous gout → neurological mechanism: reduced density of dopaminergic neurons in the striatum (caudate nucleus + putamen) and the nucleus accumbens → dopaminergic deficit + impaired dopamine release → dysfunction of the basal ganglia circuits → dystonia +(neurological compulsion—not a deliberate intention + the patient suffers from their own injuries) → dopamine supplementation (L-Dopa) does not improve self-injurious behaviors (and may worsen them) → the precise mechanisms remain debated (adenosine + dopamine + epigenetic mechanisms) + partial forms of HPRT deficiency (allelic forms): familial hyperuricemia → partial HPRT deficiency (activity 1–10 %) → Kelley-Seegmiller syndrome → hyperuricemia + gout + no self-injury → residual activity between 1–50 % → intermediate forms → imperfect genotype-phenotype correlation
- Clinical manifestations by life stage: Neonatal period and early infancy (<6 months): often unrecognized early signs → orange "sandy" appearance in diapers (urates in urine – often mistaken for blood → renal workup) → early urinary lithiasis → recurrent urinary infections → seemingly normal development in the first months → early childhood (6 months – 3 years): onset of psychomotor developmental delay → initial axial hypotonia + developing spasticity → choreoathetoid movements + dystonia → swallowing difficulties (dysphagia) + severe dysarthria → never walking independently (in complete Lesch-Nyhan syndrome) → children remain wheelchair-dependent → compulsive self-injurious behaviors (1–3 years): repeated and involuntary biting (uncontrolled + but anxiety-provoking for the patient) of lips + fingers + gums + tongue → characteristic and pathognomonic self-mutilation → the child often asks to be restrained (to prevent self-injury) → paradox: the patient suffers and fights against these behaviors but cannot control them → self-mutilation worsened by stress + fatigue + illness + resulting physical injuries: lip perforations + finger loss + blindness (eye biting) → physical restraint often necessary for protection + full neurological manifestations: severe (generalized) dystonia + spasticity + hyperreflexia + Babinski sign + athetoid movements + opisthotonus + severe dysarthria + dysphagia + feeding difficulties → despite these severe disabilities: intelligence often relatively preserved → communication possible + patients understand their situation → ++ psychological suffering → uremic manifestations: early tophaceous gout + recurrent renal lithiasis + urate nephropathy → renal failure if insufficiently treated → hematuria + renal colic from childhood
Diagnosis, treatment, and multidisciplinary care
| Aspect / Domain | Data, methods and results | Key studies and recommendations |
|---|---|---|
| Biochemical and Molecular Diagnostics HPRT erythrocyte dosage — uremia — urosuria — urate/creatinine ratio — newborn screening — HPRT1 genotyping — genetic counseling — prenatal diagnosis — orange sand diapers — Kelley-Seegmiller |
Diagnosis of Lesch-Nyhan syndrome: clinical suspicion: male child + psychomotor delay + dystonia + self-injurious behaviors + hyperuricemia → orange-colored sand in diapers (urate crystals) + recurrent urinary tract infections → initial laboratory workup: very high serum uric acid (>600–900 µmol/L) + high urinary uric acid excretion + very high urinary urate-to-creatinine ratio (N: <0.6 in children → often >3–5 in LNS) → orange sand in diapers = urate crystals → comprehensive workup: CBC + creatinine + liver function tests + serum uric acid + 24-hour urine uric acid + renal ultrasound (stones + dilation) → enzymatic confirmation: measurement of HPRT activity in erythrocytes (red blood cells) or skin fibroblasts → complete SLN: HPRT activity <0.5–1 % (near-zero) → Kelley-Seegmiller: residual activity 1–10 % → intermediate forms: 10–50 % → molecular confirmation: HPRT1 gene sequencing (chromosome Xq26.2–q26.3) → identification of the mutation → genetic counseling → forms: deletions + nonsense mutations + missense mutations + splicing variants → the genotype-phenotype correlation is imperfect → certain identical mutations can result in different phenotypes → neonatal screening: not included in the routine neonatal screening program in Quebec (metabolic screening program) → comprehensive metabolic panel if clinically suspected → prenatal diagnosis: possible if a familial mutation is identified → chorionic villus sampling (10–12 weeks’ gestation) + amniocentesis (15–18 weeks’ gestation) + molecular or enzymatic analysis + PGD (preimplantation genetic diagnosis): possible in certain centers → identify unaffected embryos prior to transfer + differential diagnosis: other causes of dystonia + psychomotor delay + self-injurious behaviors: non-SLN self-injury (different—in SLN, the compulsion is neurological + unintentional) + cerebral palsy + metabolic encephalopathy + Cornelia de Lange syndrome (self-harm + developmental delay + dysmorphia) + Prader-Willi syndrome (self-harm + hyperphagia) → serum uric acid levels are always normal in these differential diagnoses → HPRT assay is discriminatory | Lesch 1964 — American Journal of Medicine: original description of the syndrome → foundational reference + Seegmiller 1967 — Science: identification of HPRT deficiency → biochemical mechanism + Jinnah 2010 — Journal of Inherited Metabolic Disease: comprehensive review of SLN → phenotype + genotype + treatment → updated international reference + Torres 2007 — Nucleosides Nucleotides Nucleic Acids: allelic forms of HPRT deficiency + genotype-phenotype correlation + Braun 2020 — Molecular Genetics and Metabolism: SLN → update → genomics + Micheli 2005 — European Journal of Pediatric Neurology: SLN → neurology + behaviors + treatment + Canadian PKU and Allied Disorders (CPKUD): rare metabolic disorders + purine disorders + MSSS Quebec + CHU Ste-Justine + CHUSJ: reference centers for rare metabolic disorders + INESSS Quebec: allopurinol reimbursed + medical genetics |
| Treatment of Hyperuricemia — Allopurinol and Uricosuria Allopurinol — Febuxostat — Xanthine Oxidase Inhibitor — Dose — Target Uricemia — Xanthine Lithiasis — Urine Alkalinization — Hydration — Rasburicase — Urate Nephropathy — Renal Monitoring — Benzbromarone |
Treatment of hyperuricemia in Lesch-Nyhan syndrome: allopurinol — standard treatment for hyperuricemia: mechanism: xanthine oxidase inhibitor → reduces the conversion of xanthine and hypoxanthine to uric acid → accumulation of xanthine and hypoxanthine (less soluble than urate but less nephrotoxic) → normalization of serum uric acid levels → pediatric dosage: 10 mg/kg/day in 2–3 oral doses → adults: 300–600 mg/day → adjust according to renal function → goal: serum uric acid <360 µmol/L (6 mg/dL) → results: normalization of serum uric acid levels in nearly all patients + reduction in renal colic + prevention of urate nephropathy → adverse effects: skin rash (5–10% — may be severe if HLA-B*5801 positive — Asian populations) + nausea + renal toxicity if renal impairment is not corrected → CAUTION: allopurinol does NOT correct neurological symptoms + self-harming behaviors → this is essential to explain to families → xanthine oxidase: with allopurinol → xanthine accumulation → risk of xanthine lithiasis (if very high doses or dehydration) → renal ultrasound monitoring + xanthine crystals in urine → abundant hydration → febuxostat (Uloric): selective xanthine oxidase inhibitor → alternative to allopurinol in case of intolerance → limited pediatric data → positive adult data → Schumacher 2008 — NEJM (CONFIRMS trial): febuxostat 80–120 mg/day is superior to allopurinol 300 mg/day for reducing serum uric acid levels in gout → used in the SLN if allopurinol intolerance + urine alkalinization: potassium or sodium citrate → maintain urinary pH 6.5–7.0 → improves solubility of urates and xanthine → reduces risk of nephrolithiasis → sodium bicarbonate may be used + ample hydration: >2 L/m²/day → prevention of nephrolithiasis and nephropathy → rasburicase (Fasturtec): recombinant uricase → rapidly reduces serum uric acid levels → used as an emergency treatment for severe hyperuricemia with risk of acute nephropathy → not indicated for chronic treatment of G6PD deficiency + treatment monitoring: serum uric acid + uricosuria → CBC (hemolytic anemia if G6PD-deficient + allopurinol as an aggravating factor) → creatinine + annual renal ultrasound | Seegmiller 1967 — Science: HPRT + allopurinol in Lesch-Nyhan syndrome (LNS) → efficacy on uricemia → Schumacher 2008 — NEJM (CONFIRMS trial): febuxostat 80–120 mg vs allopurinol 300 mg → uricemia + Jinnah 2010 — Journal of Inherited Metabolic Disease: LNS + treatment → allopurinol + hyperuricemia + neurology + Micheli 2005 — European Journal of Pediatric Neurology: management of LNS + allopurinol + neurology + Torres 2007: allelic forms + treatment + Braun 2020 — Molecular Genetics and Metabolism: updated LNS → INESSS Quebec + RAMQ: allopurinol reimbursed for metabolic indications + febuxostat reimbursed for recognized indications + CHU Ste-Justine + CHUSJ: monitoring of rare metabolic diseases + specialist in medical biochemistry + genetics + pediatric rheumatology + pediatric neurology |
| Neurological support, self-harm behaviors, and support Dystonia — baclofen — diazepam — protective physical restraint — dental protection — GABAergic — haloperidol — S-adenosylmethionine — behavioral therapy — wheelchair — quality of life — genetic counseling — prognosis |
Neurological Care and Self-Injurious Behaviors: Understanding Self-Injurious Behaviors in SLN: self-injurious behaviors in SLN are compulsive and neurobiological → NOT intentional or deliberate self-harm → the patient suffers from their own injuries and struggles against these behaviors → often asks to be restrained (patients ask to be restrained or wear splints) → worsening during stress, fatigue, and illness → understanding this involuntary nature is fundamental for caregivers and families → ; pharmacological treatment of neurological manifestations: dystonia: baclofen (GABA-B agonist): 5–10 mg × 3/day → reduces spasticity + dystonia → Jinnah 2010: baclofen + SLN → benefits for dystonia → diazepam (benzodiazepine): anxiolysis + reduction in dystonic episodes + botulinum toxin (Botox): local injections into dystonic muscles + clonazepam: if associated with an epileptic component → levodopa-carbidopa (Sinemet): L-Dopa + SLN → data are disappointing → does not improve self-injury (may even worsen it) → used with caution if documented improvement in motor function + haloperidol (D₂ antagonist): some case reports → reduction in self-injury → limited data → not routinely recommended → S-adenosylmethionine (SAM-e): precursor for purine base synthesis → used in some centers with anecdotal results + deep brain stimulation (DBS): targeting the internal globus pallidus (GPi) or the subthalamic nucleus (STN) → limited but promising data for dystonia and self-injurious behaviors in severe forms → Mohn 2021 — Molecular Genetics and Metabolism: DBS + SLN → a few cases + variable results + physical protection — essential measures: protective physical restraint: elbow splints (to prevent biting by limiting elbow flexion) + padded gloves + protective sleeves → restraint systems allowing some freedom of movement + dental care: tooth extraction (incisors +++): controversial but often necessary to prevent bites + OR soft acrylic dentures (protects without extraction) → continuous oral protection + diet: pureed or semi-liquid → gastrostomy if severe dysphagia compromises nutrition → rehabilitation and quality of life: augmentative and alternative communication (AAC) if severe dysarthria → adapted motorized wheelchair → psychological support for families → support groups → special education program → genetic counseling: mandatory surrogacy if affected male and mother without de novo mutation → screening of sisters + cousins → prenatal diagnosis + PGD offered | Jinnah 2010 — Journal of Inherited Metabolic Disease: Neurological Management + Self-Mutilating Behaviors + SLN → Comprehensive International Review Mohn 2021 — Molecular Genetics and Metabolism: SCP + SLN → Preliminary Data Micheli 2005 — European Journal of Pediatric Neurology: SLN → Neurology + Treatment + Behaviors Lesch 1964 — American Journal of Medicine: Founding Description Braun 2020 — Molecular Genetics and Metabolism: Updated SLN → Genomics + Phenotype + Treatment SSIEM (Society for the Study of Inborn Errors of Metabolism): SLN → Rare Metabolic Disease Guidelines CHU Ste-Justine + CHUSJ Québec: Multidisciplinary Management SLN → Genetics + Pediatric Neurology + Pediatric Rheumatology + Speech Therapy + Occupational Therapy + Specialized Dental Care INESSS Québec + RAMQ: Allopurinol + Baclofen + Benzodiazepines → Reimbursed |
ℹ️
Allopurinol normalizes uric acid levels in Lesch-Nyhan syndrome but does not correct the neurological manifestations or self-mutilating behaviors—this distinction is fundamental to explain to families: SLN self-harm behaviors are compulsive and neurobiological—the patient suffers from their own injuries and struggles against these behaviors but cannot control them. Orange sand in a male infant's diapers should suggest urate lithiasis and trigger measurement of serum uric acid and the urine urate/creatinine ratio. Diagnosis relies on measuring HPRT activity in erythrocytes and molecular confirmation (HPRT1 sequencing).
Situations requiring urgent or priority specialized care
Male infant with colic (crying + restlessness) + gross hematuria or visible orange sand in diapers + recurrent urinary tract infections + very high serum uric acid on labs → Lesch-Nyhan syndrome to rule out → urgent assessment: blood uric acid + urinary urate/creatinine ratio + renal ultrasound + erythrocyte HPRT assay → consultation with medical genetics and medical biochemistry → CHU Ste-Justine or CHUSJ → initiation of allopurinol upon diagnosis confirmation + abundant hydration + urine alkalization.
Child with known SCNS + severe bites leading to deep wounds + or risk of irreversible mutilation (finger + lip + eye) → Need for physical protection → immediate restraint + elbow splints + protective gloves → specialized dental consultation to discuss mouthguard or incisor extraction → re-evaluation of associated anxiety + treatment of triggering stress + discussion of gastrostomy if dysphagia threatens nutrition.
Patient with SLN + severe dystonic crisis + opisthotonos + respiratory distress + apnea → severe dystonic crisis → urgent neurological consultation → IV or rectal diazepam + IV baclofen if available + or IM midazolam → safe positioning → if apnea → intubation + mechanical ventilation → search for triggering factor (infection + pain + stress) → re-evaluation of maintenance treatment (baclofen dose + benzodiazepines).
Consult at Clinique Omicron
Clinique Omicron physicians can identify the suggestive signs of Lesch-Nyhan syndrome (orange sand in diapers + psychomotor delay + dystonia in a boy), prescribe the initial biological workup (blood uric acid level + urinary urate/creatinine ratio), urgently refer to a specialized center for rare metabolic diseases (CHU Ste-Justine + CHUSJ), and monitor uric acid levels and kidney function in diagnosed patients on allopurinol. Consultations are available at several service points in Quebec and via telemedicine. To make an appointment, visit cliniqueomicron.ca.
The content of this page is provided for informational purposes only and is not a substitute for the advice of a physician, geneticist, or pediatric neurologist. Lesch-Nyhan syndrome is a rare metabolic disorder requiring specialized multidisciplinary care. Self-injurious behaviors are neurobiological in origin and not intentional—they require particular understanding and compassion from caregivers and families.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.